• Huiyi Yao, Ruiwen Luo, Ruoyi Tong, Yanwen Wei, Kaiteng Zheng, and Xiangdan Hu.
• The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.
• Medicine (Baltimore). 2023 Apr 14; 102 (15): e33465e33465.

BackgroundSentinel lymph node (SLN) assessment is used to treat early endometrial cancer; however, its application in advanced endometrial cancer remains controversial. Therefore, we assessed the effects of SLN assessment and lymphadenectomy (LND) on the prognosis (survival rate and primary outcome) of patients with advanced endometrial cancer.MethodsPertinent studies were selected from PubMed, Embase, Web of Science, and the Cochrane Library until March 19, 2022. Relevant studies were strictly screened according to the inclusion and exclusion criteria. Data from the included studies were extracted and their quality was evaluated. Then RevMan5.4 software was used for the meta-analysis.ResultsFour retrospective studies were included, which enrolled 7181 patients; 492 were treated with SLN and 6689 with LND. In terms of overall survival, there was no significant difference between the 2 groups (odds ratio = 1.14, 95% confidence interval: 0.92-1.41, I2 = 0%, P = .39).ConclusionsSLN assessment is an alternative to LND as a treatment modality for advanced endometrial cancer.Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.

14 keywords...

hide…